KR20020015357A - 시부트라민 및 올리스타트를 포함하는 제약 조성물 - Google Patents

시부트라민 및 올리스타트를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR20020015357A
KR20020015357A KR1020017016575A KR20017016575A KR20020015357A KR 20020015357 A KR20020015357 A KR 20020015357A KR 1020017016575 A KR1020017016575 A KR 1020017016575A KR 20017016575 A KR20017016575 A KR 20017016575A KR 20020015357 A KR20020015357 A KR 20020015357A
Authority
KR
South Korea
Prior art keywords
formula
compound
obesity
pharmaceutically acceptable
enantiomer
Prior art date
Application number
KR1020017016575A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 존 힐
Original Assignee
독터. 호르스트 하스칼, 잉에 린스
크놀 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 독터. 호르스트 하스칼, 잉에 린스, 크놀 게엠베하 filed Critical 독터. 호르스트 하스칼, 잉에 린스
Publication of KR20020015357A publication Critical patent/KR20020015357A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017016575A 1999-06-24 2000-06-16 시부트라민 및 올리스타트를 포함하는 제약 조성물 KR20020015357A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE9914744.9 1999-06-24
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
KR20020015357A true KR20020015357A (ko) 2002-02-27

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017016575A KR20020015357A (ko) 1999-06-24 2000-06-16 시부트라민 및 올리스타트를 포함하는 제약 조성물

Country Status (21)

Country Link
EP (1) EP1187606A1 (bg)
JP (1) JP2003503349A (bg)
KR (1) KR20020015357A (bg)
CN (1) CN1358092A (bg)
AU (1) AU5533200A (bg)
BG (1) BG106180A (bg)
BR (1) BR0011880A (bg)
CA (1) CA2375972A1 (bg)
CZ (1) CZ20014613A3 (bg)
GB (1) GB9914744D0 (bg)
HK (1) HK1049278A1 (bg)
HU (1) HUP0201878A3 (bg)
IL (1) IL147079A0 (bg)
MX (1) MXPA01012936A (bg)
NO (1) NO20016224L (bg)
PL (1) PL352402A1 (bg)
RU (1) RU2229289C2 (bg)
SK (1) SK18242001A3 (bg)
TR (1) TR200103699T2 (bg)
WO (1) WO2001000205A1 (bg)
ZA (1) ZA200109989B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CN101626768B (zh) 2006-09-15 2013-08-21 雷维瓦药品公司 环烷基甲胺的合成、使用方法和组合物
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
BR112014016122A8 (pt) 2011-12-30 2017-07-04 Reviva Pharmaceuticals Inc composto, e, composição farmacêutica

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
RU2229289C2 (ru) 2004-05-27
AU5533200A (en) 2001-01-31
JP2003503349A (ja) 2003-01-28
CN1358092A (zh) 2002-07-10
SK18242001A3 (sk) 2003-02-04
GB9914744D0 (en) 1999-08-25
WO2001000205A1 (en) 2001-01-04
MXPA01012936A (es) 2004-04-21
CZ20014613A3 (cs) 2003-04-16
HUP0201878A3 (en) 2005-04-28
NO20016224L (no) 2002-02-12
IL147079A0 (en) 2002-08-14
HUP0201878A2 (hu) 2003-08-28
TR200103699T2 (tr) 2002-04-22
HK1049278A1 (zh) 2003-05-09
PL352402A1 (en) 2003-08-25
ZA200109989B (en) 2003-02-26
BR0011880A (pt) 2002-03-19
NO20016224D0 (no) 2001-12-19
BG106180A (bg) 2002-08-30
EP1187606A1 (en) 2002-03-20
CA2375972A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
AU773188C (en) Method of treating eating disorders
EP1039900B1 (en) Pharmaceutical composition containing sibutramine and orlistat
US6376552B1 (en) Treatment of gallstones
KR20020015357A (ko) 시부트라민 및 올리스타트를 포함하는 제약 조성물
WO2000056315A1 (en) Treatment of pain
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
KR20020012293A (ko) 치료제
US6232347B1 (en) Treatment of osteoarthritis
AU773490B2 (en) Treatment of osteoarthritis
US6403650B1 (en) Treatment of pulmonary hypertension
US6433020B1 (en) Treatment of cardiovascular disease
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
CA2368416A1 (en) Treatment of gallstones
CA2367045A1 (en) Treatment of certain cancers associated with weight gain
WO2000056317A1 (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application